RUBIN’S REFLECTIONS

Follow on Twitter @IBDMD

Message to Dr. Rubin’s Patients Related to COVID-19 Boosters

Aug 13, 2021

Dear Friends and Patients, I hope this message finds you well. Please excuse the group nature of this message, but I did want to reach out with the latest update about COVID-19, and vaccinations. If you want to skip right to the booster info, scroll down to #5 below....

Tweetorial to Provide Updates on COVID-19 for Patients with IBD

Jul 30, 2021

View Twitter Thread To watch me deliver the full lecture and view the presentation, click here. I recently gave a lecture about COVID-19 and vaccination with specific information for patients with IBD. This lecture was recorded on July 21st, before the CDC issued...

Tweetorial to Clarify the NYT Article From 15 April and Further Explain/Clarify the UK CLARITY IBD Study

Apr 18, 2021

Tweetorial to Clarify the NYT Article From 15 April and Further Explain/Clarify the UK CLARITY IBD Study David T. Rubin View Twitter Thread I've previously commented about the CLARITY IBD Study (Kennedy, et al). paper in this forum, but it bears repeating and further...

SARS Vaccine and IBD Tweetorial Summary from December 1

Dec 5, 2020

SARS Vaccine and IBD Tweetorial Summary from December 1 David T. Rubin View Twitter Thread Here are my thoughts and a few updates about SARS-CoV-2 vaccines, and also about important implications for our IBD patients. Development of multiple SARS-CoV-2 vaccines in the...

Approach to Management and Interpretation of Testing Results in Patients with IBD, with Particular Attention to Restarting Therapy

Apr 21, 2020

By David T. Rubin, MD, Professor of Medicine, University of Chicago Medicine As testing for SARS-CoV-2 is expanded and serologic antibody testing becomes available, we are faced with a number of different clinical scenarios. I have outlined the different situations...

Three waves of Illness from the COVID-19 Pandemic

Apr 1, 2020

By David T. Rubin, MD, Professor of Medicine, University of Chicago Medicine I've been thinking about what comes next, and how can we get ahead of this, and propose the following for consideration. I believe that there will be three waves of illness from the...

Dr. David T. Rubin on “How I Treat Ulcerative Colitis”

by David Rubin | April 23, 2024 | In the Press, Presentations | 0 Comments

Dr. Rubin provides an in-depth look at the treatment of ulcerative colitis, from recent advances in therapeutic agents to setting patient expectations, positioning treatments, and monitoring for disease remission or progression. Click here for the full talk from the...

Dr. David T. Rubin Guest-Hosts IBD Drive Time

by David Rubin | June 7, 2023 | In the Press | 0 Comments

Take a listen to Dr. Rubin discuss the impact of inflammatory bowel disease on sexual function with University of Chicago's GI psychologist, Dr. Alyse Bedell, and pelvic floor physical therapist, Sarah Macaraeg.

Hospital-stay duration after IBD surgery not linked to sleep, activity

by dtrubin | December 16, 2019 | biosensor, In the Press | 0 Comments

Second-year Pritzker medical student, Yangtian Yi, received Best Abstract in Surgery at AIBD 2019 for his abstract associating length of stay for IBD surgical patients with data collected from wearable devices. His oral presentation and abstract was reported on by...

Dr. David T. Rubin on Bowel Urgency: the Next Frontier in Management of Ulcerative Colitis

by David Rubin | October 19, 2023 | In the Press | 0 Comments

Listen here as Professor David T. Rubin discusses bowel urgency in ulcerative colitis and its management with Professor Laurent Peyrin-Biroulet in a recent episode of IBDscope.

U.S. News & World Report features Dr. Rubin in “What’s the Difference Between Colitis and Crohn’s Disease?”

by dtrubin | March 20, 2019 | CD, In the Press, UC | 0 Comments

“A distinguishing feature of ulcerative colitis is that it's confined to the large intestine, which encompasses your colon and rectum, says Dr. David Rubin, chief of gastroenterology and a professor of medicine with University of Chicago Medicine....

Dr. David T. Rubin on Transabdominal Ultrasound for IBD: Lessons from STARDUST Substudy on Ustekinumab

by David Rubin | January 19, 2024 | In the Press | 0 Comments

Intestinal ultrasound has become a useful tool in assessing disease progression and pathophysiology of inflammatory bowel disease (IBD). It’s an approach to visualizing the intestines using a transabdominal ultrasound probe to provide real-time information. But could...

Dr. Rubin summarizes IBD treatment options on Medscape ReCAP

by dtrubin | July 29, 2020 | In the Press | 0 Comments

Dr. Rubin discusses the three classes of biologic therapies approved for IBD. These therapies, albeit revolutionary for patient care are limited by clearance issues, need for dose escalation, and loss of response. The arrival of small molecule therapies, such as...

Trial by Data: Chronic Disease & Data

by dtrubin | May 15, 2018 | Data, In the Press, monitoring | 0 Comments

Listen to Dr. Rubin featured on a podcast by Litmus Health, Trial by Data, exploring data-driven technologies and strategies shaping the future of clinical trials. Dr. Rubin talks about the importance of optimism in patient care and his own clinical trial using...

IBD As We Age: Thoughts on Treatment and Management For Age 40 and Beyond

by dtrubin | December 4, 2019 | QoL, Rubin's Reflections | 0 Comments

There is a growing number of people diagnosed with IBD who are defined as “elderly”. This varies in definition but can be considered those who have IBD older than 50 or older than 60 or 65. I prefer the World Health Organization definition of >65. The two different...

How Does SARS-CoV-2 Become COVID-19 and How Can We Stop It?

by dtrubin | March 26, 2020 | Coronavirus, Rubin's Reflections | 0 Comments

By David T. Rubin, MD, Professor of Medicine, University of Chicago Medicine Dear Colleagues, Here is my understanding of the different stages through which SARS-CoV-2 becomes COVID-19. I also added some thoughts on how we can prevent these stages and treat patients....